At the time of writing, Enzo Biochem, Inc. (NYSE:ENZ) has a Piotroski F-Score of 2. The F-Score may assist unveil companies with strengthening balance sheets. The score may also be used to uncloak the weak performers. Joseph Piotroski developed the F-Score which employs nine alternate variables based on the enterprise financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the nonstandard end, a stock with a score from 0-2 would be viewed as weak.
Creating a diversified stock portfolio is one way that investors may combat the unknown. Appropriate levels of exposure that include alternate market scenarios might vary from one individual investor to the next. Investors may are required to careful that they do not become too reliant on one big position. When that position is producing returns, it can be easy to assume that the owning will continue to produce positive results. If the portfolio is weighted too heavily on one or two big positions, an overall market downturn may send the investor reeling. Finding that proper portfolio balance is typically what dedicated investors strive for.
SMA 50/200
Ever wonder how investors predict positive equity price momentum? The Cross SMA 50/200, also known as the “Golden Cross” is the fifty day moving average divided by the two hundred day moving average. The SMA 50/200 for Enzo Biochem, Inc. (NYSE:ENZ) is right now 0.67687. If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average – indicating a positive equity price momentum. If the Golden Cross is less than 1, then the 50 day moving average is below the 200 day moving average, indicating that the price might drop.
The price to book ratio or market to book ratio for Enzo Biochem, Inc. (NYSE:ENZ) right now stands at 1.838344. The ratio is determined by dividing the equity price per share by the book value per share. This ratio is used to understand how the market values the equity. A ratio of under 1 typically implies that the shares are undervalued. A ratio over 1 implies that the market is willing to pay more for the shares. There are Often times many underlying factors that come into play with the Price to Book ratio so all special metrics should be considered as well.
MF Rank
The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable enterprise trading at a good price. The formula is determined by viewing at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Enzo Biochem, Inc. (NYSE:ENZ) is 15233. A enterprise with a low rank is considered a good enterprise to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.
The Q.i. Value of Enzo Biochem, Inc. (NYSE:ENZ) is 73.00000. The Q.i. Value is a useful gadget in determining if a enterprise is undervalued or not. The Q.i. Value is determined using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the enterprise is thought to be.
The C-Score is a system developed by James Montier that helps understand whether a enterprise is involved in falsifying their financial statements. The C-Score is determined by a variation of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of Enzo Biochem, Inc. (NYSE:ENZ) is 3.00000. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to understand the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 implies a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a enterprise cheating in the books.
At some point, individual investors may find themselves routinely falling prey to the lure of performance chasing. It can be highly tempting to want to be a part of a near-term stock run to the upside. Short-term investors may only be interested in these types of moves, but longer-term investors may want to be a bit more cautious. Chasing performance may end up sought-after the investor away from previously defined goals and the overall strategy. Investors who are committed to achieving long-term success may seldom are required to reshuffle the deck when the short-term clatter becomes too noisy.
Turning to Free Cash Flow Growth (FCF Growth), this is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Enzo Biochem, Inc. (NYSE:ENZ) is -1.087888. Free cash flow (FCF) is the cash produced by the enterprise minus capital expenditure. This cash is what a enterprise uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a useful gadget in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.
Stock volatility is a percentage that implies whether a stock is a desirable purchase. Investors look at the Volatility 12m to understand if a enterprise has a low volatility percentage or not over the timeframe of a year. The Volatility 12m of Enzo Biochem, Inc. (NYSE:ENZ) is 47.991300. This is determined by taking weekly log normal returns and standard deviation of the equity price over one year annualized.
The lower the number, a enterprise is thought to have low volatility. The Volatility 3m is a similar percentage calculated by the daily log normal returns and standard deviation of the equity price over 3 months. The Volatility 3m of Enzo Biochem, Inc. (NYSE:ENZ) is 61.520500. The Volatility 6m is the same, except measured over the timeframe of six months. The Volatility 6m is 54.546100.
Value Composite
The Value Composite One (VC1) is a method that investors use to understand a enterprise’s value. The VC1 of Enzo Biochem, Inc. (NYSE:ENZ) is 69. A enterprise with a value of 0 is thought to be an undervalued enterprise, while a enterprise with a value of 100 is considered an overvalued enterprise. The VC1 is determined using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is determined with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Enzo Biochem, Inc. (NYSE:ENZ) is 71.
ERP5 Rank
The ERP5 Rank is an investment gadget that analysts use to unveil undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Enzo Biochem, Inc. (NYSE:ENZ) is 15217. The lower the ERP5 rank, the more undervalued a enterprise is thought to be.
There are many traders who think that proper psychology is one of the most meaningful aspects of becoming successful in the equity market. Traders may are required to learn how to become confident while overcoming certain fears and dealing with extreme ups and downs. This may not be easy as individuals all draw out of whack of prior experiences at some level. Being able to convert outside success to the equity market may take some work. Traders who are able to overcome previous bias may be on the right path for having the proper mindset when entering the market.
